



Stellenbosch
UNIVERSITY
IYUNIVESITHI
UNIVERSITEIT

Material Transfer Agreements And Import Permits

CLIMADE Africa Working Group
7 March 2023
12h00

Suzette Grobler
Grants Manager

The National Health Act, 2003 (Section 68 of Act No 61 of 2003)

- **Regulates the import and export of human tissue, blood, blood products, cultured cells, stem cells, etc.**
- **No samples may be imported without a permit.**
- **The import permit must be underpinned by a Material Transfer Agreement**
 - text
 - text

Material Transfer Agreement (MTA)

- MTA sets out framework within parties will engage in the transfer, use and other processing of materials.
 - MTA negotiated between the legal departments of the two institutions
 - Project samples relate to requires ethical clearance (Stellenbosch University)

MTA – Information Required

- **Type of material (sample) and quantity (align to information provided on import permit application)**
 - ❖ Example: SARS-CoV2 nasal swabs
 - ❖ RNA extracted (50 tubes)
 - ❖ Cryovials of Plasma
- **Place of origin**
- **Identified potential users**
- **Describe research project. Include the manner in which and the extent to which the material may be used by the recipient**
- **Signed by both Provider and Recipient organization's legally authorised representative**
 - Timeline: depends on turn-around time of 2 legal departments

Import Permit

- **The processes for the MTA and the Import Permit cannot run concurrently**
 - Once MTA signed, import permit application can be submitted to Department of Health in South Africa.
 - Include a copy of the signed MTA with the import permit application
 - It takes three months (minimum) to receive an import permit.
 - Valid for one year.

Acknowledgements



CERI is supported by the South African Medical Research Council (SAMRC) with funds received from the National Department of Health. Sequencing activities at KRISP and CERI are supported in part by grants from the Rockefeller Foundation (HTH 017), the Abbott Pandemic Defense Coalition (APDC), the African Society for Laboratory Medicine, the National Institute of Health USA (U01 AI151698) for the United World Antivirus Research Network (UWARN) and the INFORM Africa project through IHVN (U54 TW012041), the SAMRC South African mRNA Vaccine Consortium, the South African Department of Science and Innovation (SA DSI) and the SAMRC under the BRICS JAF #2020/049 and the World Bank (TF0B8412)



